Research Article

Peptide Extract from Olivancillaria hiatula Exhibits Broad-Spectrum Antibacterial Activity

Edward Ntim Gasu,1,2 Hubert Senanu Ahor,1 and Lawrence Sheringham Borquaye1,2

1Central Laboratory, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana
2Department of Chemistry, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana

Correspondence should be addressed to Lawrence Sheringham Borquaye; slborquaye@gmail.com

Received 19 September 2018; Accepted 22 November 2018; Published 23 December 2018

Copyright © 2018 Edward Ntim Gasu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Increasing reports of infectious diseases worldwide have become a global concern in recent times. Depleted antibiotic pipelines, rapid and complex cases of antimicrobial resistance, and emergence and re-emergence of infectious disease have necessitated an urgent need for the development of new antimicrobial therapeutics, preferably with novel modes of action. Due to their distinct mode of action, antimicrobial peptides offer an interesting alternative to conventional antibiotics to deal with the problems enumerated. In this study, the antimicrobial potential of the peptide extract from the marine mollusc, Olivancillaria hiatula, was evaluated in vitro. Agar diffusion and broth dilution techniques were used to evaluate microbial susceptibility to the peptide extract. Microplate-based assays were also used to investigate time-dependent growth inhibition profiles of microbes in the presence of peptide and evaluate the peptide’s ability to modulate the activities of standard antibiotics. Both Gram-positive and Gram-negative bacteria were inhibited by the peptide extract in the agar diffusion assay. The minimum inhibitory concentration (MIC) of peptide against test microorganisms was between 0.039 and 2.5 mg/mL. At the MIC, the peptide extract was bacteriostatic towards all tested microorganisms but bactericidal to Staphylococcus aureus. In the presence of the peptide extract, a prolonged lag phase was observed for all microbes, similar to standard ciprofloxacin. When administered together, peptide extracts enhanced the activities of ciprofloxacin and cefotaxime and were antagonistic towards erythromycin but indifferent towards metronidazole. Taken together, these results show the broad-spectrum antibacterial activity of peptide extract from Olivancillaria hiatula and demonstrate that antimicrobial peptides can be employed in combination with some conventional antibiotics for improved effects.

1. Introduction

At the beginning of the 20th century, infectious diseases were reported to be the leading cause of global morbidity and mortality. The discovery of the penicillins and other antibiotics improved this grim outlook a bit, with increased optimism that the war against infectious diseases was under control [1, 2]. Between 1930 and 2000, there was a tremendous supply of antibiotics and arsenals of other antimicrobials for clinical and veterinary use. Antimicrobials such as penicillins, tetracyclines, macrolides, cephalosporins, quinolones, aminoglycosides, oxazolidines, and glycopeptides revolutionized the field of medicine and increased life expectancy remarkably [3, 4]. Infectious diseases, however, still remain a concern. Globally, they are the second leading cause of deaths and the third leading cause of death in developing countries [5, 6].

In the last few decades, the world has undeniably faced a postantibiotic era characterized by multidrug resistance, where most microbes are escaping the effect of existing antibiotics [7, 8]. To further compound the situation, there is a marked decline in research and development of antimicrobials [7] and this is a major threat to global health. This decline in the antibiotic pipeline, the inevitable development of resistance that follow the introduction of new antibiotics [9] coupled with emergence, and reemergence of infectious diseases have led to a pressing need for new antimicrobial agents to be unearthed to salvage this dire situation.

To overcome the menace of antimicrobial resistance (AMR), various strategies have been proposed. These include
combination therapy [10], supplementing antibiotics with adjuvants [11], modifying old antibiotics to improve antimicrobial activity [12], and searching nature for new antimicrobial agents [7]. While combination therapy seems to be at the risk of toxicity and antagonism, modifying old antibiotics could expand the spectrum of resistance acquisition strategies employed by microorganisms and lead to even further complications. The search for novel antimicrobial agents, antibiotics, or lead compounds with unconventional modes of action from nature is potentially a promising route to tackle the problem.

Most antibiotics owe their source to the terrestrial ecosystem: fungi, soil-borne bacteria, and some plants are examples. The aquatic (marine) ecosystem has languished behind the terrestrial ecosystem in the search for remedies with novel mechanisms of action [13]. However, exploring sources such as the marine environment could lead to the discovery of chemical and biological novelties as well [14]. A number of works on several extracts of marine organisms have shown interesting antimicrobial, antioxidant, antimalarial, anti-inflammatory, and anticancer activities. In fact, some metabolites possessing these properties have been isolated and characterized [15]. Antimicrobial peptides from marine invertebrates provide a novel class of compounds possessing remarkable antimicrobial activities as well as slower rates of resistance acquisition by bacteria [16, 17] that could be explored in the quest for new antimicrobial therapeutics.

Antimicrobial peptides (AMPs) are abundant in nature among plants and various animal families. They are mostly cationic and amphipathic. Due to their amphipathicity, they are able to achieve high concentrations in both aqueous environments and within membranes of organisms. AMPs exhibit a broad-spectrum antimicrobial activity since they constitute the first line of defense of both animals and plants against the attack of microbes. Microbial killing is usually as a result of rapid interaction of the AMP with the microbial outer membrane which leads to membrane disruption, release of cytoplasmic constituents, and a halt to cellular activities [18–21]. Little work is ongoing concerning peptides from Ghanaian marine invertebrates, but crude peptides of Galatea paradoxa and Patella rustica have been reported to possess some antimicrobial activity [22].

Olivancillaria hiatula (O. hiatula), a marine gastropod belonging to the family Olividae, is ubiquitous on the shores of Eikwe in the Western Region of Ghana. O. hiatula is benthic, and its sessile life form makes it prone to harsh environmental conditions and varying microbial attacks. We have recently shown that solvent extracts from the body tissue of O. hiatula possess impressive ability to reduce inflammation in vivo [23]. We hypothesized its whole-body tissue as a potential source of antimicrobial peptides. The antibacterial activities and antibiotic-modulating effect of peptides extracted from the whole-body tissue of O. hiatula were therefore investigated in this study.

The peptide extract from O. hiatula was observed to possess broad-spectrum antimicrobial activity against selected human pathogens. Bacterial growth kinetic studies demonstrated a prolonged lag time with a high reduction in bacterial growth within that period in the presence of peptides at subminimum inhibitory concentrations. Generally, bacteriostatic activity was observed for most of the organisms. Modulation studies revealed that the peptides enhanced the activity of ciprofloxacin and cefotaxime, antagonistic towards erythromycin but indifferent towards metronidazole activity.

2. Methods

2.1. Sample Collection and Identification. Samples were collected by convenience sampling from Eikwe (4° 58’ 00” N 2° 28’ 47” W), a town in the Nzema East Municipality of the Western Region of Ghana. They were transported on ice to laboratories in the Department of Chemistry, Kwame Nkrumah University of Science and Technology (KNUST), Kumasi, and stored at 4°C. Organism was identified with help from the Fisheries and Marine Sciences Department of the University of Ghana, Legon. The Global Biodiversity Information Facility (GBIF) database [24] was used to confirm the taxonomy and sample was identified as O. hiatula.

2.2. Peptide Extraction. The shells of the molluscs were removed and the whole-body tissues washed and blended. Hundred grams of the blended body tissue was homogenized with 60 mL of 10% (v/v) acetic acid and kept for 12 hours at 4°C. The extract obtained was centrifuged at 5000 rpm (SciSpin ONE, UK) for 10 minutes and the supernatant decanted. Ice-cold acetone (25 mL) was then added to the supernatant and kept at 4°C for 24 hours to precipitate peptides. The precipitates were collected by centrifuging at 5000 rpm for 15 minutes and discarding the supernatant. Precipitates were then frozen at -80°C. Nitrogen gas was used to blow out traces of solvents after freezing at -80°C. The peptides were reconstituted in 25% acetonitrile (ACN) prepared in 0.1% trifluoro acetic acid (TFA) to give 20 mg/mL stock solution [28] and stored at 4°C prior to use.

2.3. Characterization by Infrared Spectroscopy. The infrared spectrum of the peptide was determined using a Fourier Transform infrared (FTIR) equipment (UATR Two, PerkinElmer). The regions between 4000 cm⁻¹ and 400 cm⁻¹ were scanned. This was then followed by baseline correction. Dried extract obtained from lyophilization was used.

2.4. Antimicrobial Assays

2.4.1. Microbial Cultures. In this study, nine test bacterial strains (2 Gram-positives and 7 Gram-negatives) were used to assess the antimicrobial properties of the extracts. The Gram-positive bacteria used were Staphylococcus aureus ATCC 25923 (S. aureus) and Enterococcus faecalis ATCC 29212 (E. faecalis). Gram-negative bacteria included Escherichia coli ATCC 25922 (E. coli), Proteus mirabilis ATCC 4175 (P. mirabilis), Pseudomonas aeruginosa ATCC 4853 (P. aeruginosa), and clinical strains of Klebsiella pneumonia (K. pneumonia), Salmonella paratyphi (S. paratyphi), Neisseria gonorrhea (N. gonorrhea), and Vibrio cholera (V. cholera). All microbial strains were obtained from the Department
of Pharmaceutical Microbiology, Faculty of Pharmacy and Pharmaceutical Sciences of the College of Health Science, KNUT.

2.4.2. Inoculum Preparation. Bacterial isolates were streaked onto nutrient agar (Oxoid, United Kingdom) plates and incubated for 18–24 hours at 37°C. Using the direct colony suspension method, suspensions of the organisms were made in nutrient broth and incubated overnight at 37°C. These overnight cultures were used for the determination of antimicrobial activity using the well diffusion assay. For the remaining tests, colony suspensions in sterile saline was adjusted to 0.5 McFarland standard and further diluted in sterile double strength nutrient broth (~2 × 10⁵ CFU/mL) [29].

2.5. Agar Well Diffusion Assay. Twenty-five milliliters of freshly prepared sterile nutrient agar (cooled to 40–50°C) was poured into sterile Petri dishes containing 10 μL of overnight cultures and swirled to ensure a homogenous spread of the organisms. This was allowed to solidify. Three equidistant wells of 6 mm in both diameter and depth were made on the plates using sterile cork borers. 100 μL of prepared peptide solution was then dispensed into the wells, allowed to equilibrate at room temperature for 30 minutes, and then incubated overnight at 37°C. Zones of growth inhibition (in mm) were measured as the diameter of the clear zone around each well. The assay was performed in independent triplicates and the averages of the three experiments taken.

Ciprofloxacin (Sigma Aldrich, Michigan, USA) was used as reference antimicrobial agent (positive control) for bacteria strains while 25 % ACN in 0.1 % TFA was used as negative reference antimicrobial agent (positive control) for bacteria. The ability of peptide extracts at sub-MIC concentrations to modulate the activity of standard antibiotics was evaluated. In this experiment, the MIC of standard antibiotics against the microbes and the MIC of the antibiotics in the presence of sub-MIC concentration of the peptide were determined. The microbial resistance modulation tests were performed according to a modified procedure described by Wiegand and coworkers [29].

2.6. Minimum Inhibitory Concentration. Minimum Inhibitory Concentration (MIC) of the peptide extract was determined by the broth microdilution method described by Wiegand [29]. Ten to twenty-four serial twofold dilutions of peptide or standard antibiotic (Ciprofloxacin) were prepared to obtain a final concentration range of 2.5 to 4.88 × 10⁻⁵ mg/mL and 500 to 5.96 × 10⁻⁵ μg/mL for peptide and ciprofloxacin, respectively, in a microtiter plate. Fifty microliters of double strength nutrient broth containing an inoculum size of ~2.0 × 10⁵ CFU/mL was added to each well. The total volume of each well was 100μL. The plates were covered and incubated at 37°C for 24 hours. Twenty microliters of 1.25 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was added to each well and incubated for 30 minutes at 37°C. The MIC was determined as the lowest concentration of peptide extract or drug that inhibited growth of test organism. This was indicated by the absence of purple coloration upon the addition of the MTT dye and incubation. All tests were performed in triplicate.

2.7. Minimum Bactericidal Concentration (MBC). Minimum bactericidal concentrations (MBC) of the peptide extracts were determined by the same procedure as the MIC assay. After the 24-hour incubation period, 50 μL aliquots from wells with peptide concentrations greater than the MIC were plated on sterile agar plates. Agar plates were incubated at 37°C for 24 hours. MBC was recorded as the lowest extract concentration killing 99.9 % of the bacterial, i.e., least peptide concentration that showed no visible growth of the microorganisms on the surface of the nutrient agar. Each experiment was repeated three times.

2.8. Evaluation of Bactericidal and Bacteriostatic Capacity of Peptide Extract. The ratio of MBC/MIC was used to characterize the antimicrobial activity of peptide extracts. When the ratio of MBC/MIC ≤ 2, the effect was considered as bactericidal and a ratio ≥4 defined as bacteriostatic [25].

2.9. Microplate-Based Turbidimetric Growth Inhibition Assay. Growth inhibition of test organisms in the presence of peptide was studied using the microplate inhibition assay [30, 31] with slight modifications. In this assay, peptide extract was serially diluted from 4× MIC peptide concentration through to 0.25× MIC peptide concentration for each organism after which 50 μL of nutrient broth containing a microbial inoculum size of ~2.0 × 10⁵ CFU/mL was added. Microplates were incubated at 37°C and optical density at 600 nm (OD600.) determined at 2 hourly intervals with a microplate reader (Synergy H1 multimode plate reader, Germany). The OD600 values obtained were plotted against time and were used to illustrate the inhibitory activity of the peptide of O. hiatula against the various test organisms.

2.10. Modulation Studies. The ability of peptide extracts at sub-MIC concentrations to modulate the activity of standard antibiotics was evaluated. In this experiment, the MIC of standard antibiotics against the microbes and the MIC of the antibiotics in the presence of sub-MIC concentration of the peptide were determined. The microbial resistance modulation tests were performed according to a modified procedure described by Wiegand and coworkers [29]. Twenty-four serial twofold dilutions of standard antibiotics; Ciprofloxacin (Sigma Aldrich), Metronidazole (Sigma Aldrich), Erythromycin (Alfa Aesar), and cefotaxime (Alfa Aesar) were prepared to obtain final concentration ranges of 500 to 5.96 × 10⁻⁵ μg/mL. Fifty microliters of nutrient broth containing a microbial inoculum size of ~2.0 × 10⁵ CFU/mL was added to each well. The reference antibiotics were tested against all microorganisms. MICs were determined after incubation of plates for 24 hours and upon the addition MTT to the medium in the wells.

Subinhibitory concentrations of 20 μg/mL of the peptide solution and various dilutions of standard antibiotics plus the same inoculum size were mixed and then incubated overnight at 37°C. MICs of antibiotics in the presence of the peptides were determined as described earlier. All tests were performed in triplicate.

Modulation factor (MF) was calculated and used to evaluate the antimicrobial effects of the peptide extract on the MIC of various antibiotic used.

\[
MF = \frac{\text{MIC (antibiotic)}}{\text{MIC (antibiotic + modulator)}}
\]
Figure 1: Fourier Transform infrared (FTIR) spectrum of peptide extract of *Olivancillaria hiatula*. Amides A & B bands spans 3100–3500 cm\(^{-1}\), Amide I band is from 1600 to 1700 cm\(^{-1}\), Amide II band is from 1480 to 1600 cm\(^{-1}\), and the region from 500 to 1300 cm\(^{-1}\) represents Amides III–VI bands [26, 27].

Table 1: Zones of inhibition (mm) of peptide extract against test microorganisms.

| Microorganism (Gram status) | Peptide Extract (5 mg/ml) | Positive control Cipro (1 mg/ml) | Negative control |
|-----------------------------|---------------------------|----------------------------------|------------------|
| *E. coli* (-)               | 30.9 ± 0.2                | 51.5 ± 1.3                       | -                |
| *K. pneumonia* (-)          | 28.9 ± 0.8                | 48.8 ± 1.2                       | -                |
| *S. paratyphi* (-)          | 27.4 ± 0.5*               | 25.0 ± 6.1                       | -                |
| *P. mirabilis* (-)          | 12.1 ± 0.6                | 41.0 ± 0.2                       | -                |
| *N. gonorrhoea* (-)         | 31.0 ± 0.4                | 40.0 ± 0.8                       | -                |
| *V. cholera* (-)            | 30.0 ± 0.7*               | 40.3 ± 0.6                       | -                |
| *P. aeruginosa* (-)         | 27.0 ± 0.7                | 53.3 ± 0.9                       | -                |
| *S. aureus* (+)             | 28.5 ± 2.1                | 39.2 ± 0.9                       | -                |
| *E. faecalis* (+)           | 33.2 ± 3.0*               | 46.5 ± 1.9                       | -                |

Values reported as mean ± standard deviation of three replicate experiments; * and # activity at 10 mg/mL and 50 mg/mL, respectively (ZI not observed at 5 mg/mL); negative control (25% ACN in 0.1% TFA).

A modulation factor >2 was set as the cut-off for biologically significant modulation [32].

The change in MIC was computed using [33]

\[
\text{Change in MIC} = \left( \frac{\text{MIC (Antibiotic)} - \text{MIC (Antibiotic + Peptide)}}{\text{MIC (Antibiotic)}} \right) \times 100.
\]

2.1. Data Analyses. GraphPad Prism Version 6.0 for Windows (GraphPad Software, San Diego, CA, USA) and Microsoft Excel 2007 were used for all data analyses and graphs.

3. Results

3.1. Infrared Characterization. The spectrum obtained from the FTIR showed prominent peaks of a typical peptide. Prominent peaks consistent with stretching and bending vibrations of N-H, C=O and C-H were observed (Figure 1).

3.2. Antimicrobial Assay. The peptide extract showed a broad-spectrum antimicrobial activity with impressive activities against all microorganisms. All extracts were tested at a concentration of 5 mg/mL for the agar diffusion assay. The highest zone of inhibition (ZI) was recorded against *N. gonorrhoea* while no zone of clearance was observed against *V. cholera*, *S. paratyphi*, and *E. faecalis* at this concentration. When the concentrations were increased between 10 and 50 mg/mL, however, clear zones of inhibition were observed for those 3 microorganisms (Table 1).

3.3. Minimum Inhibitory Concentration (MIC) of Extracts. Peptide extract from *O. hiatula* demonstrated really good antimicrobial activity with very low MICs recorded. MICs ranged from 2.5 to 0.039 mg/mL against all test organisms. Gram-positive organisms recorded a relatively high MIC...
| Microorganism        | MIC (mg/mL) | MBC (mg/mL) | MBC/MIC | Effect       |
|----------------------|-------------|-------------|---------|--------------|
| *E. coli* (-)        | 0.625       | >2.5        | >4      | static       |
| *K. pneumonia* (-)   | 1.25        | >2.5        | >2      | static       |
| *S. paratyphi* (-)   | 0.625       | 2.5         | 4       | static       |
| *P. mirabilis* (-)   | 0.039       | >2.5        | >4      | static       |
| *N. gonorrhea* (-)   | 0.156       | 2.5         | >4      | static       |
| *V. cholera* (-)     | 0.315       | 2.5         | >4      | static       |
| *P. mirabilis* (-)   | 0.039       | 1.25        | >4      | static       |
| *S. aureus* (+)      | 2.5         | 2.5         | 1       | Cidal        |
| *E. faecalis* (+)    | 2.5         | >2.5        | >1      | Cidal / static |

MIC and MBC experiments were replicated thrice; MIC, minimum inhibitory concentration; MBC, minimum bactericidal concentration; MBC/MIC ≤ 2 implies bactericidal; MBC/MIC ≥ 4 implies bacteriostatic [25].

| Organism            | MIC (µg/mL) | MF     | Change in MIC (%) |
|---------------------|-------------|--------|-------------------|
| *E. coli* (-)       | 1.95        | 2053   | 99.95%            |
| *K. pneumonia* (-)  | 0.00095     | 8      | 87.50%            |
| *S. paratyphi* (-)  | 125.00      | 16383  | 99.99%            |
| *P. mirabilis* (-)  | 0.00048     | 16     | 50.00%            |
| *N. gonorrhea* (-)  | 125.00      | 2      | 50.00%            |
| *V. cholera* (-)    | 3.91        | 4116   | 99.98%            |
| *P. aeruginosa* (-) | 0.24        | 126    | 99.99%            |
| *S. aureus* (+)     | 15.63       | 8      | 87.50%            |
| *E. faecalis* (+)   | 0.24        | 64     | 98.44%            |

MIC experiments were replicated thrice; change in MIC computed using equation (2).

3.4. Minimum Bactericidal Concentration (MBC). The MBC and the ratio of MBC to MIC were determined for the peptide extract against all test organisms. This ratio indicated the microbistatic or microbicidal nature of the peptide extract against the test organisms. The lowest MBC (1.25 mg/mL) was recorded for *P. aeruginosa* while relatively higher MBC (≥ 2.5 mg/mL) of peptide were recorded for the remaining test organisms. From the ratio of MBC to MIC, the peptide was seen to have a microbicidal effect against *S. aureus* and a microbistatic action against the remaining test organisms (Table 2).

3.5. Microplate Turbidimetric Growth Inhibition Assay. In the growth inhibition assay of the peptide extract against the test organisms, the growth curves of the test organisms in the presence of 4× MIC, 2× MIC, MIC, 0.5× MIC, and 0.25× MIC of the peptide extract were reduced comparative to the growth curves of the control (test organism in the absence of peptide). The lag phases of the test organisms were prolonged for an average of 16 hours while the log phases were also reduced in the presence of the peptide. Growth curves of most test organisms flattened during the 24-hour incubation period in the presence of 2× MIC and 4× MIC of peptide concentration while this effect was observed at even the MIC of ciprofloxacin (Figures 2 and 3). The effects of the peptide extract in inhibiting the growth of the test organism were observed to be concentration dependent (Figure 2).

3.6. Antibiotic Modulation. Peptide extract of *O. hiataula* at sub-MIC concentration of 20 µg/mL had noticeable effects on the response of test organism to antibiotics with modulation factor ranging from <0.25 to 524288 (Tables 3–6). When 20 µg/mL of peptide extract was added to varying concentrations of ciprofloxacin and test organisms, the MIC of ciprofloxacin reduced markedly for all test organisms by a factor as high as about 16, 000 (Table 3). Sub-MIC concentration of peptide extract also modulated the action of cefotaxime positively against test organisms (Table 4). There was a reduction in the MIC of cefotaxime in the presence of the peptide extract for all test organisms except *S. aureus* and *N. gonorrhea* where an increase in MIC was observed. The MIC of *N. gonorrhea* actually doubled under the experimental conditions (Table 4).

The peptide extract did not have any noticeable effect on metronidazole (Table 6) but was antagonistic to erythromycin (Table 5).
Figure 2: Growth curves of test microorganisms in the presence of varying concentrations of peptide extract. Each data point is the average of 3 replicate experiments (MIC, minimum inhibitory concentration; GC, growth control).

Table 4: Co-modulation studies: MICs of Cefotaxime plus 20 μg/mL of peptide extract.

| Organism          | Cef (μg/mL) | Cef + P (μg/mL) | MF | Change in MIC (%) |
|-------------------|-------------|-----------------|----|-------------------|
| E. coli (-)       | 31.25       | 1.95            | 16 | 93.75^a           |
| K. pneumonia (-)  | 31.25       | 3.91            | 8  | 87.50^a           |
| S. paratyphi (-)  | 62.5        | 3.91            | 16 | 93.75^a           |
| P. mirabilis (-)  | 31.25       | 0.24            | 130| 99.22^a           |
| N. gonorrhoea (-) | 31.25       | 62.50           | 0.5|                   |
| V. cholera (-)    | 62.5        | 1.19 × 10^-4    | 525210 | 99.99^a          |
| P. aeruginosa (-) | 31.25       | 1.19 × 10^-4    | 262605 | 100.00^a         |
| S. aureus (+)     | 250.00      | > 250.00        | <1 | 100.00^a         |
| E. faecalis (+)   | 31.25       | 1.95            | 16 | 93.75^a           |

MIC experiments were replicated thrice; change in MIC computed using equation (2).
MF: modulation factor, Cef: cefotaxime, P: peptide extract, and R: reduction in MIC, I: increase in MIC.
Figure 3: Growth curves of test microorganisms in the presence of varying concentrations of standard ciprofloxacin drug. Each data point is the average of 3 replicate experiments (MIC, minimum inhibitory concentration; GC, growth control).

Table 5: Co-modulation studies: MICs of Erythromycin plus 20 μg/mL of peptide extract.

| Organism            | MIC (μg/mL) | Eryt + CP | MF | Change in MIC (%) |
|---------------------|-------------|-----------|----|-------------------|
| E. coli            | 125         | 125       | 1  | N                 |
| K. pneumonia       | 78          | >7.8      | <1 | >100<sup>f</sup>  |
| S. paratyphi       | 250         | >500      | <0.50 | >100<sup>f</sup> |
| P. mirabilis       | 125         | 250       | 0.50 | 100<sup>f</sup>  |
| N. gonorrhoea      | 500         | >500      | <1 | >100<sup>f</sup>  |
| V. cholera         | 125         | >500      | <0.25 | >100<sup>f</sup> |
| P. aeruginosa      | 125         | >500      | <0.25 | >100<sup>f</sup> |
| S. aureus          | >500        | >500      | <1.00 | >100<sup>f</sup> |
| E. faecalis        | 0.24        | >7.8      | <0.03 | >100<sup>f</sup> |

MIC experiments were replicated thrice; change in MIC computed using equation (2).
MF: modulation factor, Eryt: erythromycin, P: peptide extract, N: no change, and F: increase in MIC.
Table 6: Co-modulation studies: MIC values of metronidazole plus 20 μg/mL of peptide extract.

| Organism               | MIC (µg/mL) | Met + CP | MF | Change in MIC (%) |
|------------------------|-------------|----------|----|-------------------|
| E. coli                | >500        | >500     | <1 | >100^f             |
| K. pneumonia           | >500        | >500     | <1 | >100^f             |
| S. paratyphi           | >500        | >500     | <1 | >100^f             |
| P. mirabilis           | >500        | >500     | <1 | >100^f             |
| N. gonorrhea           | >500        | >500     | <1 | >100^f             |
| V. cholera             | >500        | >500     | <1 | >100^f             |
| P. aeruginosa          | >500        | >500     | <1 | >100^f             |
| S. aureus              | >500        | >500     | <1 | >100^f             |
| E. faecalis            | >500        | 250      | >1 | <50^a              |

MIC experiments were replicated thrice; change in MIC computed using equation (2).
MF: modulation factor, Met: Metronidazole, P: peptide extract, R: reduction in mic, and I: increase in MIC

4. Discussions

Various methods exist for the isolation of peptides from marine invertebrates. In this work, we have utilized the whole-body tissue of *O. hiutula* as our source of antimicrobial peptides. Ice-cold acetone precipitation of peptides from whole-body tissue homogenate afforded crude peptides in appreciable quantities.

The FTIR spectrum of the extract obtained was consistent with reported vibrational spectra of peptides [26, 27, 34]. Amide I band, which is a direct consequence of the carbonyl (C=O) stretching vibrations, was observed at about 1650 cm⁻¹. N-H bending and C-N stretching vibrations are the major contributors to Amide II bands and are usually observed from 1480 to 1575 cm⁻¹. In this spectrum, Amide II bands turned out to be more prominent with strong absorptions recorded in this region. Amides A and B bands can be observed between 3200 and 3500 cm⁻¹. These are usually due to N-H stretching vibrations. Peaks corresponding to Amides III–VI regions (500–1300 cm⁻¹) can also be seen in the spectrum. Together, these peaks are indicative of a sample predominantly made up of peptides. IR spectra can be used to estimate secondary structural elements. It is difficult to make any such deductions from the spectrum of this extract since it is presumably a mixture and could contain a number of different peptides. However, the absence of strong Amide I absorptions is conspicuous. Based on this observation, it could be speculated that the extract is rich in α-helical peptides [26, 34].

Antimicrobial peptides (AMPs) usually exhibit broad-spectrum antimicrobial activity and have been suggested as an alternative to counter the menace of antimicrobial resistance. Because AMPs are usually membrane targeting, microbial resistance would probably involve the architectural redesigning and/or compositional variation of the entire cell lipid membrane of the microorganism [21]. Such a venture would most likely be very costly and difficult to achieve for microorganisms. AMPs therefore represent a viable therapeutic option.

Peptide extract from *O. hiutula* was active against both Gram-positive and Gram-negative bacteria. Microbial susceptibility was evaluated using the agar well diffusion and broth microdilution methods. Even though some microbes (*S. paratyphi, V. cholera, and E. faecalis*) required much higher peptide concentration for activity to be observed in the agar diffusion assay, they showed really good activities in the broth microdilution test. The broth microdilution assay is regarded as being more sensitive relative to the agar diffusion assay for screening antimicrobial natural products [35]. Properties of the natural product such as pH, solubility, volatility and diffusion in agar all influence results of the agar diffusion assay but not broth microdilution assay [36, 37]. The low MICs recorded against *N. gonorrhea* and *P. aeruginosa* is impressive and hence extract is considered to be very active [37]. In general, the MIC values recorded are much lower than those recorded for peptide extracts from *Patella rustica* and *Galatea paradoxa* [22] as well as methanol and ethyl acetate extracts of *Littorina littorea* and *Galatea paradoxa* [38]. These MICs, however, are in the range of those recorded for the antimicrobial peptide pexiganan, an antimicrobial peptide that has advanced furthest in clinical trials for the treatment of diabetic foot ulcers. MICs for pexiganan ranged from 16 to 32 μg/mL [39, 40]. There is a strong positive correlation between α-helical content and antimicrobial activity [41, 42]. The impressive activities recorded against both Gram-positive and Gram-negative bacteria supports the notion that the major secondary structural elements in *O. hiutula* peptide extract are α-helices, which was speculated from the IR data.

To investigate the kind of inhibitory effects that the peptide extract had on the various bacteria studied, the minimum bactericidal concentration (MBC), defined as the lowest extract concentration killing 99.9 % of the bacterial inocula after 24-hour incubation at 37°C, was recorded. At the MIC, a bacteriostatic effect was observed for all bacteria, except *S. aureus* where a bactericidal effect was observed. Above the MIC, peptide extract was found to possess a bactericidal effect. The activity of most AMPs is concentration dependent. An increase in peptide: lipid ratio across the membrane of microorganism greatly enhances the peptide’s ability to penetrate and disrupt membrane integrity. Ion channel formation, transmembrane pore formation, and membrane rupture which all result in microbial death are more prevalent at higher peptide concentrations [43]. This effect can be observed clearly in the growth curves of the
various bacteria in the presence of varying peptide concentrations where a prolonged lag phase is recorded at 2× and 4× MIC. The growth curves of *S. aureus*, *S. paratyphi*, *P. mirabilis*, and *P. aeruginosa* and to a lesser extent *E. faecalis* in the presence of peptides (Figure 2) were similar in shape to that of the standard drug, ciprofloxacin (Figure 3).

While therapeutic agents can be used in isolation to elicit specific effect(s), combination therapy is fast becoming the norm due to several advantages associated with it. Combination therapy could possibly reduce emergence of drug resistant microbes as the microorganism has to adapt to two or more drugs with different *modus operandi*. Toxicity associated with high doses could also be eliminated in combination therapy since lower doses of the drugs will be required to achieve comparable levels of efficacy in single drug therapy. Finally, the range of pathogens that could be targeted may be expanded depending on the individual drugs present in that particular combination [44]. Identification of AMPs that can be combined with orthodox antibiotics to be used for the treatment of infections has a good potential to expand available therapeutic options.

To evaluate the possible effect of the peptide extract of *O. hiatula* on some standard antibiotics, modulation experiments were set up. Subinhibitory concentration of peptide extract remarkably decreased the MICs of ciprofloxacin against all test microorganisms. When peptide was combined with cefotaxime, the MICs against almost all test microorganisms were also reduced. For erythromycin and metronidazole, a different trend was observed, with higher MICs being recorded for erythromycin and no appreciable change observed in the case of metronidazole. Both sets of antagonistic and synergistic effects of antimicrobial peptides in combination with antibiotics have been reported in literature [45, 46]. The synergistic interaction between peptides and antibiotics could be a result of the membrane permeability action of peptides or pore formation in the bacterial membrane. This leads to disruption of membrane integrity and easy penetration of antibiotics into bacterial cells where they cause greater damage [39, 40, 46]. The antimicrobial peptides, WR12 and D-IK8, have been shown to possess potent synergism with most topical antibiotics (fusidic acid and mupirocin) and systemic antibiotics (daptomycin, teicoplanin, vancomycin, linezolid, ciprofloxacin, meropenem, and oxacillin) [46]. Short peptide chains are known to confer bacterial resistance towards some macrolide antibiotics, especially erythromycin. Macrolide resistance occurs via modification of the drug binding site (either via allosteric mutations of direct mutations of amino acid residues in the vicinity of the binding pocket) [45, 47], action of specialized antibiotic efflux pumps [48], and the action of short peptides [45, 49]. Short peptides bind to the macrolide and form an inactive complex or act directly on the ribosome to inhibit or terminate translation [45].

5. Conclusions

The broad-spectrum antibacterial activity of the peptide extract of *O. hiatula* has demonstrated this study. Peptide extract was shown to be bacteriostatic at the MIC but bactericidal at twice and quadruple MICs. In the presence of the peptide extract, a prolonged lag phase was observed in the growth patterns of all test microorganisms. The peptide extract was also found to be synergistic when used with ciprofloxacin and cefotaxime but antagonistic towards erythromycin and indifferent to metronidazole. Together, these results demonstrate the utility of peptide extracts from *O. hiatula* as potential source of potent antimicrobial agents. Efforts to isolate and characterize the antimicrobial peptides in the extract mix are currently underway in our laboratories.

Data Availability

The data used to support the findings of this study are included within the article.

Disclosure

Part of this work was presented as a poster at the “7th Ghana Science Association. Research Seminar and Poster Presentations” held at the Kwame Nkrumah University of Science and Technology, Kumasi, Ghana, in April 2018.

Conflicts of Interest

All authors declare no competing financial, professional, or personal interests that might have influenced the performance or presentation of the work described in this manuscript.

Authors’ Contributions

Lawrence Sheringham Borquaye conceived the study. All experiments were designed by Lawrence Sheringham Borquaye, Edward Ntim Gasu, and Hubert Senanu Ahor. Samples were collected by Edward Ntim Gasu. Hubert Senanu Ahor and Edward Ntim Gasu carried out all the experiments. Data analysis was by Lawrence Sheringham Borquaye, Edward Ntim Gasu and Hubert Senanu Ahor. Manuscript was prepared by Lawrence Sheringham Borquaye, Hubert Senanu Ahor, and Edward Ntim Gasu. All authors read and approved the final manuscript.

Acknowledgments

The authors are grateful to the Departments of Chemistry and Pharmaceutical Microbiology as well as the Central Laboratory and all of KNUST for the use of their facilities for this study. The authors appreciate Dr. Edmund Ekuadzi of the Department of Pharmacognosy, KNUST, and Dr. Nathaniel Owusu Boadi of the Department of Chemistry, KNUST, for helpful discussions. Authors also acknowledge Mr. Francis Amankwaah of the Department of Pharmaceutical Microbiology, KNUST, for technical support.
References

[1] H. Yoneyama and R. Katsumata, “Antibiotic resistance in bacteria and its future for novel antibiotic development,” Bioscience, Biotechnology, and Biochemistry, vol. 70, no. 5, pp. 1060–1075, 2006.

[2] A. S. Fauci, N. A. Touchette, and G. K. Folkers, “Emerging Infectious Diseases: A 10-Year Perspective from the National Institute of Allergy and Infectious Diseases,” Emerging Infectious Diseases, vol. 11, no. 4, pp. 519–525, 2005.

[3] A. L. Demain and S. Sanchez, “Microbial drug discovery: 80 years of progress,” The Journal of Antibiotics, vol. 62, no. 1, pp. 5–16, 2009.

[4] J. Lederberg, “Infectious history,” Science, vol. 288, no. 5464, pp. 287–293, 2000.

[5] A. S. Fauci, “Infectious diseases: Considerations for the 21st century,” Clinical Infectious Diseases, vol. 32, no. 5, pp. 675–685, 2001.

[6] C. Nathan, “Antibiotics at the crossroads,” Nature, vol. 431, no. 7011, pp. 899–902, 2004.

[7] B. Spellberg, M. Blaser, R. J. Guidos et al., “Combating antimicrobial resistance: policy recommendations to save lives,” Clinical Infectious Diseases, vol. 52, no. 5, pp. S397–S428, 2011.

[8] B. R. Nithya, B. P. Gladstone, J. Rodriguez-Ban˜ o et al., “EpideMiology and control measures of OutBreaks due to Antibiotic-Resistant orGanisms in Europe (EMBARGO): A systematic review protocol,” BMJ Open, vol. 7, no. 1, 2017.

[9] S. R. Norrby, C. E. Nord, and R. Finch, “Lack of development of new antimicrobial drugs: a potential serious threat to public health,” The Lancet Infectious Diseases, vol. 5, no. 2, pp. 115–119, 2005.

[10] M. A. Fischbach, “Combination therapies for combating antimicrobial resistance,” Current Opinion in Microbiology, vol. 14, no. 5, pp. 519–523, 2011.

[11] M. Zasloff, “Antimicrobial peptides, innate immunity, and the normally sterile urinary tract,” Journal of the American Society of Nephrology, vol. 18, no. 11, pp. 2810–2816, 2007.

[12] A. Okano, N. A. Isley, and D. L. Boger, “Peripheral modifications of [4(1CH,NH)1T]; vancomycin with added synergistic mechanisms of action provide durable and potent antibiotics,” Proceedings of the National Academy of Sciences, 2017.

[13] R. Montaser and H. Luesch, “Marine natural products: A new wave of drugs?” Future Medicinal Chemistry, vol. 3, no. 12, pp. 1475–1489, 2011.

[14] W. H. Gerwick and B. S. Moore, “Lessons from the past and charting the future of marine natural products drug discovery and chemical biology,” Chemistry & Biology, vol. 19, no. 1, pp. 85–98, 2012.

[15] J. W. Blunt, B. R. Copp, R. A. Keyzers, M. H. G. Munro, and M. R. Frisvad, “Marine natural products,” Natural Product Reports, vol. 31, no. 2, pp. 160–258, 2014.

[16] C. Sherlina Daphny, M. Arputha Bibiana, R. Vengatesan, P. Selvamani, and S. Latha, “Antimicrobial Peptides–A Milestone for developing antibiotics against drug resistant infectious pathogens,” Journal of Pharmaceutical Sciences and Research, vol. 7, no. 4, pp. 226–230, 2015.

[17] J. M. Sierra, E. Fusté, F. Rabanal, T. Vinuesa, and M. Viñas, “An overview of antimicrobial peptides and the latest advances in their development,” Expert Opinion on Biological Therapy, vol. 17, no. 6, pp. 663–676, 2017.

[18] A. C. Rios, C. G. Moutinho, F. C. Pinto, F. S. Del Fiol, A. Jozala, M. V. Chaud et al., “Alternatives to overcoming bacterial resistances: State-of-the-art,” Microbiological Research, vol. 191, pp. 51–80, 2016.

[19] Y. Shai, “Mode of action of membrane active antimicrobial peptides,” Biopolymers, vol. 66, no. 4, pp. 236–248, 2002.

[20] Y. Huang, J. Huang, and Y. Chen, “Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria,” Protein Cell, vol. 1, pp. 143–152, 2010.

[21] M. Zasloff, “Antimicrobial peptides of multicellular organisms,” Nature, vol. 415, no. 6870, pp. 389–395, 2002.

[22] L. S. Borquaye, G. Darko, E. Ocansey, and E. Ankomah, “Antimicrobial and antioxidant properties of the crude peptide extracts of Galatea paradoxo and Patella rustica,” SpringerPlus, vol. 4, no. 1, 2015.

[23] L. S. Borquaye, G. Darko, M. K. Laryea et al., “Anti-inflammatory activities of extracts from Oliva sp., Patella rustica, and Littorina littorea collected from Ghana’s coastal shorelines,” Cogent Biology, vol. 3, no. 1, 2017.

[24] “GBIF Backbone Taxonomy,” 2016.

[25] K. Konaté, J. F. Mavoungou, A. N. Lepengué et al., “Antibacterial activity against β-lactamase producing Meticillin and Ampicillin-resistant Staphylococcus aureus: Fractional Inhibitory Concentration Index (FICI) determination,” Annals of Clinical Microbiology and Antimicrobials, vol. 11, article no. 18, 2012.

[26] W. Gallagher, “FTIR analysis of protein structure,” Course Man Chem, vol. 455, 2009.

[27] J. Kong and S. Yu, “Fourier transform infrared spectroscopic analysis of protein secondary structural states,” Acta Biochimica et Biophysica Sinica, vol. 39, no. 8, pp. 549–559, 2007.

[28] N. Sathyana, E. R. Chaithanya, P. R. Anil Kumar, K. S. Sruthy, and R. Philip, “Comparison of the antimicrobial potential of the crude peptides from various groups of marine molluscs,” International Journal of Research in Marine Sciences, vol. 3, pp. 16–22, 2014.

[29] I. Wiegand, K. Hilpert, and R. E. W. Hancock, “Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances,” Nature Protocols, vol. 3, no. 2, pp. 163–175, 2008.

[30] P. P. Vijayakumar and P. M. Muriana, “A microplate growth inhibition assay for screening bacteriocins against listeria monocytogenes to differentiate their mode-of-action,” Biomolecules, vol. 5, no. 2, pp. 1178–1194, 2015.

[31] J. Campbell, “High-throughput assessment of bacterial growth inhibition by optical density measurements,” Current Protocols in Chemical Biology, vol. 2, no. 4, pp. 195–208, 2010.

[32] B. Gröbler, O. Kunert, and F. Bucar, “Compounds of Alpinia katsumadai as potential efflux inhibitors in Mycobacterium smegmatis,” Bioorganic & Medicinal Chemistry, vol. 20, no. 8, pp. 2701–2706, 2012.

[33] C. Agyare, J. Antwi Apen, F. Adu, E. Kesseh, and Y. Duah Boaky, “Antimicrobial, Antibiotic Resistance Modulation and Cytotoxicity Studies of Different Extracts of Pupalia lappacea,” Pharmacologia, vol. 6, no. 6, pp. 244–257, 2015.

[34] W. K. Surewicz, H. H. Mantsch, and D. Chapman, “Determination of Protein Secondary Structure by Fourier Transform Infrared Spectroscopy: A Critical Assessment,” Biochemistry, vol. 32, no. 2, pp. 389–394, 1993.

[35] L. Scorzoni, T. Benaducci, A. M. F. Almeida, D. H. S. Silva, V. S. Bolzani, and M. J. S. Mendes-Giannini, “Comparative study
of disk diffusion and microdilution methods for evaluation of antifungal activity of natural compounds against medical yeasts Candida spp and Cryptococcus sp, Revista de Ciências Farmacêuticas Básica e Aplicada, vol. 28, no. 1, pp. 25–34, 2007.

[36] A. Pauli, “Anticandidal low molecular compounds from higher plants with special reference to compounds from essential oils,” Medicinal Research Reviews, vol. 26, no. 2, pp. 223–268, 2006.

[37] P. Cos, A. J. Vlietinck, D. V. Berghe, and L. Maes, “Anti-infective potential of natural products: how to develop a stronger in vitro ‘proof-of-concept’,” Journal of Ethnopharmacology, vol. 106, no. 3, pp. 290–302, 2006.

[38] L. S. Borquaye, G. Darko, N. Oklu, C. Anson-Yevu, A. Abasio, and G. Li, “Antimicrobial and antioxidant activities of ethyl acetate and methanol extracts of Littorina littorea and Galatea paradoxa,” Cogent Chemistry, vol. 2, no. 1, 2016.

[39] R. K. Flamm, P. R. Rhomberg, K. M. Simpson, D. J. Farrell, H. S. Sader, and R. N. Jones, “In vitro spectrum of pexiganan activity when tested against pathogens from diabetic foot infections and with selected resistance mechanisms,” Antimicrobial Agents and Chemotherapy, vol. 59, no. 3, pp. 1751–1754, 2015.

[40] Y. Ge, D. L. MacDonald, K. J. Holroyd, C. Thornsberry, H. Wexler, and M. Zasloff, “In vitro antibacterial properties of pexiganan, an analog of magainin,” Antimicrobial Agents and Chemotherapy, vol. 43, no. 4, pp. 782–788, 1999.

[41] K. A. Brogden, “Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?” Nature Reviews Microbiology, vol. 3, no. 3, pp. 238–250, 2005.

[42] C. B. Park, K.-S. Yi, K. Matsuzaki, M. S. Kim, and S. C. Kim, “Structure-activity analysis of buforin II, a histone H2A-derived antimicrobial peptide: the proline hinge is responsible for the cell-penetrating ability of buforin II,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 15, pp. 8245–8250, 2000.

[43] J. D. F. Hale and R. E. W. Hancock, “Alternative mechanisms of action of cationic antimicrobial peptides on bacteria,” Expert Review of Anti-infective Therapy, vol. 5, no. 6, pp. 951–959, 2007.

[44] H. M. Nguyen and C. J. Graber, “Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: Is combination therapy the answer?” Journal of Antimicrobial Chemotherapy, vol. 65, no. 1, pp. 24–36, 2009.

[45] T. Tenson and A. S. Mankin, “Short peptides conferring resistance to macrolide antibiotics,” Peptides, vol. 22, no. 10, pp. 1661–1668, 2001.

[46] M. F. Mohamed, A. Abdelkhalek, and M. N. Seleem, “Evaluation of short synthetic antimicrobial peptides for treatment of drug-resistant and intracellular Staphylococcus aureus,” Scientific Reports, vol. 6, 2016.

[47] S. T. Gregory and A. E. Dahlberg, “Erythromycin resistance mutations in ribosomal proteins L22 and L4 perturb the higher order structure of 23 S ribosomal RNA,” Journal of Molecular Biology, vol. 289, no. 4, pp. 827–834, 1999.

[48] J. Sutcliffe, “Resistance to macrolides mediated by efflux mechanisms,” Current Opinion in Anti-infective Investigational Drugs, vol. 1, pp. 403–412, 1999.

[49] T. Tenson, L. Xiong, P. Kloss, and A. S. Mankin, “Erythromycin resistance peptides selected from random peptide libraries,” The Journal of Biological Chemistry, vol. 272, no. 28, pp. 17425–17430, 1997.